Malika Kazic-Legueux

Novartis (China) — China

Biochemistry, Genetics and Molecular Biology · Life Sciences

5h-index335citations77works1.02yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Melanoma and MAPK Pathways(44), PI3K/AKT/mTOR signaling in cancer(36), Protein Tyrosine Phosphatases(26), Synthesis and biological activity(16), Chronic Lymphocytic Leukemia Research(11)

Publications77 total

Promise and Challenge of β-Lactone Electrophiles to Target Aspartate 12 of Mutant KRAS<sup>G12D</sup>
Journal of Medicinal Chemistry·2025· 1 cited
Data from CRISPR Screening Identifies Mechanisms of Resistance to KRAS&lt;sup&gt;G12C&lt;/sup&gt; and SHP2 Inhibitor Combinations in Non–Small Cell Lung Cancer
2023Open Access
Supplementary Data from CRISPR Screening Identifies Mechanisms of Resistance to KRAS&lt;sup&gt;G12C&lt;/sup&gt; and SHP2 Inhibitor Combinations in Non–Small Cell Lung Cancer
2023Open Access
Supplementary Data from CRISPR Screening Identifies Mechanisms of Resistance to KRAS&lt;sup&gt;G12C&lt;/sup&gt; and SHP2 Inhibitor Combinations in Non–Small Cell Lung Cancer
2023Open Access
Data from CRISPR Screening Identifies Mechanisms of Resistance to KRAS&lt;sup&gt;G12C&lt;/sup&gt; and SHP2 Inhibitor Combinations in Non–Small Cell Lung Cancer
2023Open Access
CRISPR Screening Identifies Mechanisms of Resistance to KRASG12C and SHP2 Inhibitor Combinations in Non–Small Cell Lung Cancer
Cancer Research·2023· 24 citedOpen Access
Supplementary Figure 4 from SHP2 Inhibition Overcomes RTK-Mediated Pathway Reactivation in KRAS-Mutant Tumors Treated with MEK Inhibitors
2023Open Access
Supplementary Table 3 from SHP2 Inhibition Overcomes RTK-Mediated Pathway Reactivation in KRAS-Mutant Tumors Treated with MEK Inhibitors
2023Open Access
Supplementary Figure 4 from SHP2 Inhibition Overcomes RTK-Mediated Pathway Reactivation in KRAS-Mutant Tumors Treated with MEK Inhibitors
2023Open Access
Supplementary Figure 2 from SHP2 Inhibition Overcomes RTK-Mediated Pathway Reactivation in KRAS-Mutant Tumors Treated with MEK Inhibitors
2023Open Access
Supplementary Figure 5 from Characterization of the Mechanism of Action of the Pan Class I PI3K Inhibitor NVP-BKM120 across a Broad Range of Concentrations
2023Open Access
Supplementary Figure 3 from Characterization of the Mechanism of Action of the Pan Class I PI3K Inhibitor NVP-BKM120 across a Broad Range of Concentrations
2023Open Access
Data from Characterization of the Mechanism of Action of the Pan Class I PI3K Inhibitor NVP-BKM120 across a Broad Range of Concentrations
2023Open Access
Supplementary Table 2 from SHP2 Inhibition Overcomes RTK-Mediated Pathway Reactivation in KRAS-Mutant Tumors Treated with MEK Inhibitors
2023Open Access
Data from Characterization of the Mechanism of Action of the Pan Class I PI3K Inhibitor NVP-BKM120 across a Broad Range of Concentrations
2023Open Access
Supplementary Methods, Table 1, and Figure Legends from Characterization of the Mechanism of Action of the Pan Class I PI3K Inhibitor NVP-BKM120 across a Broad Range of Concentrations
2023Open Access
Supplementary Figure 5 from Characterization of the Mechanism of Action of the Pan Class I PI3K Inhibitor NVP-BKM120 across a Broad Range of Concentrations
2023Open Access
Supplementary Figure 2 from SHP2 Inhibition Overcomes RTK-Mediated Pathway Reactivation in KRAS-Mutant Tumors Treated with MEK Inhibitors
2023Open Access
Supplementary Figure 1 from SHP2 Inhibition Overcomes RTK-Mediated Pathway Reactivation in KRAS-Mutant Tumors Treated with MEK Inhibitors
2023Open Access
Supplementary Figure 2 from Characterization of the Mechanism of Action of the Pan Class I PI3K Inhibitor NVP-BKM120 across a Broad Range of Concentrations
2023Open Access
page 1 of 4Next →

Frequent Co-authors

Saskia M. Brachmann(50), Sauveur-Michel Maira(34), Daniel Guthy(32), Éric Billy(32), Audrey Kauffmann(30), William R. Sellers(30), Francesco Hofmann(30), Hans Voshol(23), David A. Ruddy(22), Barbara Herkert(18), Sandra Mollé(18), Christian Schnell(18), Thomas Ferrat(18), Janina Juengert(18), Grégory Marszalek(18), Mark Stump(18), Mitko Ristov(18), Michael N. Hall(18), Hélène Erasimus(17), Keith Calkins(17)